OKUR OnKure Therapeutics, Inc.
OnKure Therapeutics, Inc. (OKUR) is expected to report earnings on November 3, 2026, after the market close. The consensus earnings estimate is a loss of $0.56 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -3.4% since its last earnings release on August 4, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About OnKure Therapeutics, Inc.
OnKure Inc. is a clinical-stage biopharmaceutical company. It focused on the discovery and development of precision medicines which target biologically validated drivers of cancers. The company is currently developing OKI-219. OnKure Inc., formerly known as Reneo Pharmaceuticals Inc., is based in IRVINE, Calif.
Sector
Healthcare
Industry
Biotechnology